Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 3
2006 5
2007 3
2008 9
2009 13
2010 11
2011 8
2012 2
2013 4
2014 3
2015 7
2016 3
2017 1
2018 4
2019 2
2020 1
2021 3
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Among authors: sweetenham j. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Moskowitz CH, et al. Among authors: sweetenham j. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. Blood. 2018. PMID: 30266774 Free article. Clinical Trial.
Adult lymphoblastic lymphoma.
Portell CA, Sweetenham JW. Portell CA, et al. Among authors: sweetenham jw. Cancer J. 2012 Sep-Oct;18(5):432-8. doi: 10.1097/PPO.0b013e31826b1232. Cancer J. 2012. PMID: 23006948 Review.
Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.
Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Kraut J, et al. Among authors: sweetenham jw. J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. J Oncol Pract. 2019. PMID: 30883256 No abstract available.
Surviving surveillance.
Sweetenham JW. Sweetenham JW. Oncology (Williston Park). 2015 Apr;29(4):228. Oncology (Williston Park). 2015. PMID: 25952484 Free article. No abstract available.
Lymphoblastic lymphoma in adults.
Sweetenham JW. Sweetenham JW. Curr Hematol Malig Rep. 2006 Dec;1(4):241-7. doi: 10.1007/s11899-006-0005-8. Curr Hematol Malig Rep. 2006. PMID: 20425319 Review.
Review of clinical radioimmunotherapy.
Pohlman B, Sweetenham J, Macklis RM. Pohlman B, et al. Among authors: sweetenham j. Expert Rev Anticancer Ther. 2006 Mar;6(3):445-61. doi: 10.1586/14737140.6.3.445. Expert Rev Anticancer Ther. 2006. PMID: 16503861 Review.
Mantle cell lymphoma: observation to transplantation.
Rajabi B, Sweetenham JW. Rajabi B, et al. Among authors: sweetenham jw. Ther Adv Hematol. 2015 Feb;6(1):37-48. doi: 10.1177/2040620714561579. Ther Adv Hematol. 2015. PMID: 25642314 Free PMC article. Review.
Following aggressive B-cell lymphoma.
Sweetenham JW. Sweetenham JW. Blood. 2015 Jun 11;125(24):3673-4. doi: 10.1182/blood-2015-04-641738. Blood. 2015. PMID: 26069330 Free article.
Highly aggressive lymphomas in adults.
Sweetenham JW. Sweetenham JW. Hematol Oncol Clin North Am. 2008 Oct;22(5):965-78, ix. doi: 10.1016/j.hoc.2008.07.009. Hematol Oncol Clin North Am. 2008. PMID: 18954746 Review.
77 results